We hope inotersen will be available to patients in the UK very soon,” he added. After a confidential price cut, Akcea has persuaded NICE to change its position on Tegsedi, paving the way for the ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...

Alnylam has beaten off competition in the US from RNAi company Ionis, which is developing a rival therapy for hATTR, Tegsedi (inotersen). Inotersen has been approved in the EU, where Alnylam’s ...

AstraZeneca and Ionis Pharmaceuticals’ polyneuropathy drug has won approval in the European Union (EU), where it will be marketed as Wainzua (eplontersen). The drug has been approved to treat ...

Prothena Corporation focuses on neurodegenerative diseases with a diverse pipeline, including Birtamimab for AL amyloidosis, which is in a phase 3 trial. Despite past trial failures, Birtamimab ...

It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma TA1046 12 March 2025 12 March 2025 ...